Healthcare101

 The Global Point of Care and Rapid Diagnostics Market is expected to reach USD 75.5 billion by 2027 from an estimated USD 45.4 billion in 2022, at a CAGR of 10.7% from 2022 to 2027. The growth of the point-of-care diagnostics market can be attributed to the high prevalence of respiratory diseases such as influenza, COVID diseases, cardiac diseases, and infectious disease, (where POC tests can greatly improve the management of these diseases, especially in developing countries where access to timely medical care is a challenge and the healthcare infrastructure is antiquated and sparse). Moreover, growing accessibility of POCT products through online platforms, supportive govt. Policies, and rising number of CLIA-waived POC tests. healthcare decentralization and greater investments and funding for product development are expected to accelerate the growth point of care diagnostics market in the coming years. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.a

 The Leukapheresis Market is projected to reach USD 98 million by 2027 from USD 65 million in 2022, at a CAGR of 8.5% between 2022 and 2027. While the high cost of therapeutic leukapheresis and leukopaks is expected to restrain the global Leukapheresis market during the forecast period, the increasing incidence and prevalence of leukemia, and the high demand for leukopaks in clinical research are some of the factors set to drive the market. Key Players: Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany). Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US) Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148 In this report, the overal

 The Diabetes Care Devices (BRIC) Market size is projected to reach USD 4.3 billion by 2025 from USD 1.7 billion in 2020, at a CAGR of 16.2% during the forecast period. Factors such as the increasing diabetic population, the rising awareness of diabetes treatment and management, and favorable national health strategies are expected to drive the growth of the diabetes care devices (BRIC) market. Key Market Players: Medtronic plc (Ireland), B. Braun (Germany), DexCom, Inc. (US), Abbott (US), F. Hoffman-La Roche Ltd. (Switzerland), Ascensia Diabetes Care Holdings AS (Switzerland), LifeScan (US), AgaMatrix Holdings LLC (US), Acon Laboratories, Inc. (US), ARKRAY USA, Inc. (US), Novo Nordisk A/S (Denmark), Becton, Dickinson and Company (US), Sanofi (France), Terumo Corporation (Japan), SD Biosensor, Inc. (South Korea), MicroGene Diagnostic Systems Pvt. Ltd. (India), Ypsomed (Switzerland), Dr. Morepen (India), Sinocare, Inc. (China), Bionime Corporation (Taiwan), and Rossmax International